Morris & Dickson Acquires Prodigy Health in Strategic Push into Specialty Pharmaceuticals

SHREVEPORT, LA – January 26, 2026 – Morris & Dickson (M&D), the nation’s largest independent pharmaceutical distributor, has finalized its acquisition of Prodigy Health, a specialized distribution and services company, in a move that significantly bolsters its capabilities in the high-growth specialty drug market.

The transaction integrates Prodigy Health's expertise, particularly in plasma-derived therapies, into M&D’s expansive network. The deal is positioned to enhance support for a wide range of healthcare providers—from hospitals and clinics to infusion centers—at a time when demand for complex, high-value treatments is surging. All Prodigy Health employees will be retained as part of the deal, with the acquired entity operating under the new name ProdigyMD.

“This transaction reflects our long-term commitment to specialty distribution and alternative sites of care,” said Jody Hatcher, chief executive officer of Morris & Dickson, in a statement announcing the completion of the deal. “Our focus is on expanding access to critical therapies while preserving continuity for customers and operating with regulatory integrity that is consistent with our independent, customer-first values.”

A Strategic Play in a Booming Market

The acquisition is not just a routine business expansion; it is a calculated maneuver to capture a larger share of the most dynamic sector in pharmaceuticals. The specialty drug market, which includes treatments for complex and chronic conditions like cancer, autoimmune disorders, and rare diseases, is experiencing explosive growth. Industry projections indicate that specialty medicines could account for as much as 50% of all global pharmaceutical spending within the next few years.

Driving this trend are significant advancements in biotechnology, a robust pipeline of biologic drugs, and an aging population with a rising prevalence of chronic illnesses. Within this space, the plasma-derived therapies market—a core competency of the newly acquired Prodigy Health—is itself a formidable segment. Valued at over $16.8 billion in 2022, the global plasma therapy market is projected to grow at a compound annual rate of over 7%, driven by its essential role in treating immunodeficiencies and other life-threatening conditions.

By absorbing Prodigy Health’s specialized infrastructure and knowledge base, Morris & Dickson is positioning itself to capitalize on these powerful market tailwinds. The move allows the company to offer a more comprehensive portfolio to manufacturers and a more reliable supply of complex products to healthcare providers navigating the challenges of modern patient care.

The Independent Edge in a Consolidated Field

Morris & Dickson's identity as the nation's largest independent distributor is a key element of its strategy. The U.S. pharmaceutical distribution landscape is overwhelmingly dominated by three corporate giants—McKesson, Cardinal Health, and Cencora—which collectively handle approximately 90% of the market. In this consolidated environment, independent distributors must carve out distinct advantages to compete effectively.

This acquisition appears to be a core part of that strategy. By doubling down on the high-complexity, high-touch specialty market, M&D can differentiate itself from larger, more generalized wholesalers. Specialty drugs often require meticulous handling, such as cold-chain storage and transportation, along with sophisticated patient support and reimbursement services—areas where a focused, specialized distributor can excel.

“By combining Morris & Dickson’s national reach with Prodigy Health’s specialty and plasma expertise, we are creating a reliable channel that helps manufacturers reach diverse sites of care while maintaining the service levels and regulatory integrity they expect,” noted Jason Hanks, chief commercial officer of Morris & Dickson. This new, broader platform provides an attractive alternative for drug manufacturers seeking distribution partners with both scale and specialized focus.

Ensuring Continuity for Critical Therapies

For the hospitals, specialty pharmacies, and infusion centers that rely on these life-sustaining medications, the most pressing question during any acquisition is the continuity of service. A disruption in the supply chain for plasma therapies or other specialty drugs can have immediate and severe consequences for patients.

Morris & Dickson has publicly committed to a seamless transition, outlining a “phased integration process” designed to maintain stability. The newly formed ProdigyMD will operate as a distinct unit within the M&D family, a structure intended to preserve its specialized operational expertise while leveraging the parent company's national scale. This approach aims to ensure that customers experience no interruption in ordering, fulfillment, or support.

“This is a meaningful step forward in our specialty strategy,” said Layne Martin, head of specialty at Morris & Dickson. “By bringing Prodigy Health’s purpose-built plasma and specialty expertise into the Morris & Dickson family, we are strengthening our ability to support complex therapies while maintaining the service and compliance our customers expect. Our immediate focus is disciplined execution and personalized customer support.”

The integration promises to extend the availability of Prodigy’s specialized tools and services to M&D’s broader customer base, ultimately enhancing the capabilities of providers at alternative sites of care. As healthcare delivery continues to shift from traditional hospital settings to outpatient clinics and home infusion, a robust and reliable specialty distribution network becomes ever more critical. This strategic alignment aims to build a more resilient and responsive supply chain, ensuring that the most complex therapies can reliably reach the patients who depend on them.